Literature DB >> 23423190

Magnetic resonance imaging reveals therapeutic effects of interferon-beta on cytokine-induced reactivation of rat model of multiple sclerosis.

Sébastien Serres1, Claire Bristow, Rocío M de Pablos, Doron Merkler, Manuel Sarmiento Soto, Nicola R Sibson, Daniel C Anthony.   

Abstract

Interferon-β (IFN-β) drugs are considered to derive their beneficial effects on multiple sclerosis (MS) progression via their antiinflammatory properties, but the precise mechanism of action remains unclear. Here, we sought to discover how IFN-β impacts on inflammation-associated aggravation of MS-like lesions in rat. Animals with dormant focal experimental allergic encephalomyelitis (EAE) lesions were challenged intravenously with a replication-deficient adenovirus vector carrying interleukin (IL)-1β cDNA (AdIL-1β). Aggravation of inflammation and demyelination within the focal EAE lesion was observed after AdIL-1β injection with associated changes in tissue structure detected by diffusion and magnetization transfer imaging. Postgadolinium-DTPA T1-weighted images revealed contrast enhancement in the ipsilateral meninges, indicating breakdown of the blood-cerebrospinal fluid barrier, and increased left/right regional cerebral blood volume ratio was also observed after AdIL-1β injection. To determine the role of IFN-β on reactivation of the EAE lesion, rats were treated with therapeutic doses of IFN-β and focal EAE lesions showed significantly reduced reactivation in response to systemic AdIL-1β injection. In conclusion, these findings indicate a central role for peripheral IL-1β expression in the mechanism of MS lesion reactivation and that the therapeutic effects of IFN-β may, at least in part, reflect suppression of the effects of peripheral inflammation on MS lesion pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23423190      PMCID: PMC3652701          DOI: 10.1038/jcbfm.2013.12

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  46 in total

Review 1.  Interleukin 1 in the brain: biology, pathology and therapeutic target.

Authors:  N J Rothwell; G N Luheshi
Journal:  Trends Neurosci       Date:  2000-12       Impact factor: 13.837

2.  B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Authors:  Martin S Weber; Thomas Prod'homme; Juan C Patarroyo; Nicolas Molnarfi; Tara Karnezis; Klaus Lehmann-Horn; Dimitry M Danilenko; Jeffrey Eastham-Anderson; Anthony J Slavin; Christopher Linington; Claude C A Bernard; Flavius Martin; Scott S Zamvil
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

Review 3.  Interleukin-1 and inflammatory neurodegeneration.

Authors:  A Simi; N Tsakiri; P Wang; N J Rothwell
Journal:  Biochem Soc Trans       Date:  2007-11       Impact factor: 5.407

4.  Characterization of white matter damage in animal models of multiple sclerosis by magnetization transfer ratio and quantitative mapping of the apparent bound proton fraction f.

Authors:  M Rausch; Ps Tofts; P Lervik; Ar Walmsley; A Mir; A Schubart; T Seabrook
Journal:  Mult Scler       Date:  2008-10-29       Impact factor: 6.312

5.  Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells.

Authors:  H Lochmüller; A Jani; J Huard; S Prescott; M Simoneau; B Massie; G Karpati; G Acsadi
Journal:  Hum Gene Ther       Date:  1994-12       Impact factor: 5.695

6.  Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA.

Authors:  I Tsunoda; N D Tolley; D J Theil; J L Whitton; H Kobayashi; R S Fujinami
Journal:  Brain Pathol       Date:  1999-07       Impact factor: 6.508

7.  Prospective study on the relationship between infections and multiple sclerosis exacerbations.

Authors:  D Buljevac; H Z Flach; W C J Hop; D Hijdra; J D Laman; H F J Savelkoul; F G A van Der Meché; P A van Doorn; R Q Hintzen
Journal:  Brain       Date:  2002-05       Impact factor: 13.501

8.  Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption.

Authors:  Wouter B Veldhuis; Sarah Floris; Peter H van der Meide; Ine M P Vos; Helga E de Vries; Christien D Dijkstra; Peter R Bär; Klaas Nicolay
Journal:  J Cereb Blood Flow Metab       Date:  2003-09       Impact factor: 6.200

9.  Endothelial cell integrin laminin receptor expression in multiple sclerosis lesions.

Authors:  R A Sobel; J R Hinojoza; A Maeda; M Chen
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

Review 10.  Multiple sclerosis: the environment and causation.

Authors:  Gavin Giovannoni; George Ebers
Journal:  Curr Opin Neurol       Date:  2007-06       Impact factor: 5.710

View more
  3 in total

1.  Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disability.

Authors:  David Paling; Esben Thade Petersen; Daniel J Tozer; Daniel R Altmann; Claudia A M Wheeler-Kingshott; Raju Kapoor; David H Miller; Xavier Golay
Journal:  J Cereb Blood Flow Metab       Date:  2013-09-18       Impact factor: 6.200

Review 2.  Antibodies as Mediators of Brain Pathology.

Authors:  Lior Brimberg; Simone Mader; Yuichiro Fujieda; Yoshiyuki Arinuma; Czeslawa Kowal; Bruce T Volpe; Betty Diamond
Journal:  Trends Immunol       Date:  2015-10-19       Impact factor: 16.687

Review 3.  Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation.

Authors:  Andrew J Steelman
Journal:  Front Immunol       Date:  2015-10-19       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.